The fate of generic pharma industry and particularly accessibility of medicines will be decided when multinational Bayer's case against the government comes up for hearing in the Delhi High Court on Monday...This is one of rare instances an MNC suing the Indian government to introduce higher intellectual property standards, than what is required under Trips agreement (trade-related aspects of intellectual property rights), experts say.